Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock
15 janv. 2019 22h04 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
14 janv. 2019 16h35 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
Stemline Therapeutics Announces Submission of European Marketing Authorization Application (MAA) for ELZONRIS™
07 janv. 2019 09h50 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...
Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
02 janv. 2019 07h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...
Stemline Therapeutics Recaps Key Clinical Data Presentations from the American Society of Hematology (ASH) Annual Meeting
06 déc. 2018 07h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting
30 nov. 2018 07h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...
Stemline Therapeutics Announces that European Medicines Agency (EMA) Grants Accelerated Assessment for planned ELZONRIS Marketing Authorization Application (MAA)
20 nov. 2018 07h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)
16 nov. 2018 07h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
Stemline Therapeutics Reports Third Quarter 2018 Financial Results
08 nov. 2018 16h01 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
Stemline Therapeutics Announces Four ELZONRIS Presentations, Including an Oral Presentation, at Upcoming ASH Meeting
02 nov. 2018 07h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...